Jundan Xie

Jundan Xie

Auto-generated profile, based on publicly available information

Jundan Xie

National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2023 in Blood
Verified
Journal Article
Closed access
PDF file
JXJundan Xie
Jundan Xie
XBXiebing Bao
Xiebing Bao
SXSheng-Li Xue
Sheng-Li Xue
HSHongjie Shen
Hongjie Shen
JCJiannong Cen
Jiannong Cen
DWDepei Wu
Depei Wu
Xie et al present results of a multicenter, single-arm phase 2 trial of venetoclax and decitabine as frontline treatment in 42 younger adults (median age 39 years) with newly diagnosed adverse risk acute myeloblastic leukemia (AML). Remission was achieved in 39 of 42 patients (93%), 36 of whom went on to allogeneic stem cell transplant. Efficacy is encouraging, with estimated 12-month overall survival, event-free survival, and duration of response being 82%, 61%, and 65% respectively.